Quality of life survey will be publicised globally
Europa Uomo’s new quality of life study will be launched on 25th October, when men with prostate cancer around the world will be asked to complete an online questionnaire about life after treatment. The EUPROMS 2.0 study will build on the interest in, and influence of, its 2019-2020 EUPROMS (Europa Uomo Patient Reported Outcome Study) research.
The original EUPROMS study was based on a survey asking men to provide important information about symptoms and changes in their life after treatment for prostate cancer. It drew nearly 3,000 responses, and the analysis and findings were reported at international scientific meetings and in influential journals. Findings have also proved important in campaigning for better prostate cancer early detection programmes in the EU.
Now, the EUPROMS 2.0 survey will provide more detailed information that will also help inform moves to provide better services and early diagnosis for prostate cancer. Responses provided to the questionnaire will help answer vital questions such as:
- Is the quality of life of men with prostate cancer better if early detection programmes are in use?
- Is quality of life better if men are treated in multidisciplinary centres?
- To what extent does quality of life decline in the later stages, when patients are receiving ADT and chemotherapy?
Europa Uomo is aiming to publicise the survey globally, as well as throughout Europe, to allow global comparisons.
“Through the EUPROMS surveys, patients can have power, and do something for other patients,” said Europa Uomo Chairman André Deschamps. “There are important points on quality of life that only we, as patients, can judge, and that is why we have set up EUPROMS 2.0.”
“When we started EUPROMS two years ago, I would not have imagined what an impact it would have had.” Its findings have been presented to European politicians who are currently deciding whether to recommended prostate cancer early detection programmes throughout Europe. “They are listening,” said André Deschamps.
People who responded to the first questionnaire are being encouraged to respond again. Answers will remain confidential. All responses will be anonymous. The analysis will again be conducted by urology researchers at Erasmus MC, Rotterdam.